Publications
26
Citations
431
Est. group size
—
Recurring co-author estimate
Active years
14
Publishing since 2013
Typically publishes in teams of ~24 · 6% small-team papers (≤3 authors) · across 9 venues
- Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes
Blood Cancer Journal · 2026
- How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?
Leukemia · 2026
- Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q
Blood Advances · 2026
- Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes
Blood · 2025
- Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes
Blood · 2025
- Influence of <i>TP53</i> gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion
Blood · 2024
- Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))
Blood · 2024
- Treatment of Richter Transformation of Chronic Lymphocytic Leukemia in the Modern Era
Cancers · 2023
- The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia
Therapeutic Advances in Hematology · 2023
- Outcomes of patients with therapy‐related myeloid neoplasms after treatment with poly(<scp>ADP</scp>‐ribose) polymerase proteins inhibitors for solid tumours
British Journal of Haematology · 2023
- A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory <i>FLT3</i> Mutated Acute Myeloid Leukemia (AML)
Blood · 2023
- <i>TP53 G</i>ene <i>a</i>llelic State in Myelodysplastic Syndromes (MDS) with Isolated 5q Deletion
Blood · 2023
- Outcomes of myeloid malignancies in patients previously treated with PARP inhibitors for solid malignancies: A single institution experience.
Journal of Clinical Oncology · 2023
- Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients
Blood · 2022
- PITFALLS AND FAILURES IN CREATING AN NG/ET TUBE DETECTION TOOL VIA CXR AND MACHINE LEARNING
CHEST Journal · 2020
- Blood×8
- American Journal of Hematology×2
- CHEST Journal×2
- Journal of Clinical Oncology×2
- Cancers×1
- Allyson Waller
Medicine · The Ohio State University
- Yue-Zhong Wu
Medicine · The Ohio State University
- Ying Huang
Medicine · The Ohio State University
- George Deeb
Medicine · University of Michigan
- C. D. Bloomfield
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile